In a filing, Zymeworks BC Inc revealed its Director EcoR1 Capital, LLC acquired Company’s shares for reported $0.57 million on May 15 ’25. In the deal valued at $11.43 per share,49,502 shares were bought. As a result of this transaction, EcoR1 Capital, LLC now holds 17,877,989 shares worth roughly $322.88 million.
Then, EcoR1 Capital, LLC bought 5,919 shares, generating $69,738 in total proceeds. Upon buying the shares at $11.78, the Director now owns 17,883,908 shares.
Before that, EcoR1 Capital, LLC bought 73,953 shares. Zymeworks BC Inc shares valued at $825,589 were divested by the Director at a price of $11.16 per share. As a result of the transaction, EcoR1 Capital, LLC now holds 17,773,727 shares, worth roughly $320.99 million.
B. Riley Securities initiated its Zymeworks BC Inc [ZYME] rating to a Buy in a research note published on October 10, 2025; the price target was $30. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. JP Morgan also remained covering ZYME and has increased its forecast on December 16, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 07, 2024. It rated ZYME as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of ZYME
On Friday, Zymeworks BC Inc [NASDAQ:ZYME] saw its stock jump 6.74% to $18.06. Over the last five days, the stock has gained 6.61%. Zymeworks BC Inc shares have risen nearly 44.13% since the year began. Nevertheless, the stocks have risen 23.36% over the past one year.
How much short interest is there in Zymeworks BC Inc?
A steep rise in short interest was recorded in Zymeworks BC Inc stocks on 2025-09-30, growing by 32997.0 shares to a total of 6.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 6.89 million shares. There was a rise of 0.48%, which implies that there is a positive sentiment for the stock.
